NICE approve dapagliflozin

NICE has issued a Final Appraisal Determination (FAD) for the first-in-class type 2 diabetes drug dapagliflozin (Forxiga). Currently in the UK, more than one million patients are on either metformin alone or insulin. The FAD recommends dapagliflozin to be used in combination with metformin instead of a sulphonylurea (SU) in certain patients. These are patients for whom an SU is not tolerated/contraindicated or are at significant risk of hypoglycaemia or its consequences. Furthermore, the addition of dapagliflozin to metformin may be preferable to a thiazolidinedione if further weight gain is a concern.   The NICE recommendation means that adults with type